NASDAQ : KLRA

Kailera Therapeutics, Inc.

$18.55 USD

$0.23 (1.26%)

Volume
339.82K
Average Volume
930.23K
Market Capitalization
$2.4B
P/E Ratio
-14.72
Dividend Yield
0.00%
Price Target
$42.00
Year High
$28.23
Year Low
$17.61
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$12.01
Company Overview

NASDAQ

Ronald C. Renaud Jr.

Biotechnology

Healthcare

KLRA

145

US

USD

www.kailera.com

(781) 317-0290

482931102

0002096997

Liquidity Metrics

-0.03

12.01

12.01

3.45

0.00

Sales & Valuation

-$

0.00

-6.14

-19.65

-1.04

Profitability

-$1.26

-$148.96M

0.00%

0.00%

41.79%

-21.52%

P/E Metrics

-14.72

-0.15

-0.15

Analyst Price Target & Rating

$42.00

$48.00

$36.00

Sell

2/5

0 Analysts

-55.83%

Poll Results

About Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock

Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations. ...

2 Beaten-Down GLP-1 Stocks to Buy on the Dip

2026-07-15 01:00:00

Don't wait until clinical milestones send their share prices soaring.

Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win

2026-07-09 05:00:34

Kailera is building a multi-modal obesity franchise with exclusive global rights to Hengrui Pharma's obesity portfolio, leveraging late-stage assets and ongoing data. KLRA's robust cash position—over $1.3 billion post-IPO—funds operations through mid-2028, supporting multiple pivotal trial readouts before further capital is needed. Pipeline catalysts include global Phase 3 trials for ribupatide and promising Phase 2/3 data for oral GLP-1 candidates, targeting differentiated efficacy and convenience.

Why Is Kailera Therapeutics Stock Falling Tuesday?

2026-07-07 12:45:27

Kailera Therapeutics Inc. (NASDAQ:KLRA) stock fell about 9% on Tuesday after the company reported positive topline results from two Phase 3 trials of its oral GLP-1 drug candidate HRS-7535/KAI-7535 in China.

Kailera's GLP-1 drug meets main goal of late-stage trials

2026-07-07 07:09:07

Kailera ​Therapeutics said ‌on ​Tuesday ​its GLP-1 ⁠drug ​for patients ​with diabetes ​and ​obesity met the ‌main ⁠goal of ​two-late ​stage ⁠trials.

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

2026-06-29 07:30:00

Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Ka

Biotech ETF Index Surges 10% After Rebalance

2026-06-25 11:31:47

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.

3 Under-the-Radar Stocks to Buy and Hold for a Decade

2026-06-16 03:30:00

All three could become highly prominent biotech companies within 10 years.

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

2026-06-05 19:32:00

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with v omiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively Phase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China, demonstrated similar exposure, tolerability, and weight reduction in participants of Asian and non-Asian descent SHANGHAI and WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced clinical results for ribupatide (also known as HRS9531 or KAI-9531), a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight, presented at the 86th Scientific Sessions of the American Diabetes Association (ADA).

Frequently Asked Questions

What is the current Kailera Therapeutics, Inc. (KLRA) stock price?

Kailera Therapeutics, Inc.(NASDAQ:KLRA) stock price is $18.55 in the last trading session. During the trading session, KLRA stock reached the peak price of $28.23 while $17.61 was the lowest point it dropped to. The percentage change in KLRA stock occurred in the recent session was 1.26% while the dollar amount for the price change in KLRA stock was $0.23.

KLRA's industry and sector of operation?

The NASDAQ listed KLRA is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of KLRA?

Kathleen Tregoning | Chief Corporate Affairs Officer
Corey Manchester | Treasurer
Scott Wasserman | Chief Medical Officer
Maura Gavaghan | Vice President of Corporate Communications & Investor Relations
Ronald C. Renaud Jr. | President, CEO & Director

How many employees does KLRA have?

Number of KLRA employees currently stands at 145. KLRA operates from 180 Third Avenue, 4th Floor, Waltham, MA 02451, US.

Link for KLRA official website?

Official Website of KLRA is: www.kailera.com

How do I contact KLRA?

KLRA could be contacted at phone #(781) 317-0290 and can also be accessed through its website. KLRA operates from 180 Third Avenue, 4th Floor, Waltham, MA 02451, US.

How many shares of KLRA are traded daily?

The average number of KLRA shares traded daily for last 3 months was 930.23K.

What is the market cap of KLRA currently?

The market value of KLRA currently stands at $2.4B with its latest stock price at $18.55